Clinical trials
Patient Safety clinical trials
Below are recruiting patient safety clinical trials, each written for real people, not researchers. We’re tracking 1,355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02852213RecruitingPhase 1
Dose-check study for children with AADC deficiency using brain surgery
This Phase 1 trial tests how safe different treatment doses are for children with AADC deficiency, using MRI-guided brain surgery. It may help improve movement and developmental progress after standard medicines did not work well enough.
San Francisco, CaliforniaAges 2 years+ - NCT07784296Recruiting
Triple combination therapy for high blood pressure in Korean adults
This study tests a three-drug combination pill for high blood pressure in Korean adults. It aims to see if this treatment is safe and effective.
Gyeonggi-doAges Any age - NCT06809764Recruiting
Study of T-DXd in Chinese patients with HER2m NSCLC
This study looks at how safe and effective the drug T-DXd (trastuzumab deruxtecan) is for Chinese patients with a specific type of lung cancer that has a HER2 mutation. It helps understand if this treatment works well in real-world settings.
BeijingAges 18 years+ - NCT06578624RecruitingPhase 1/Phase 2
SA53-OS for advanced solid tumors
This trial tests an experimental drug (SA53-OS) for people with advanced solid tumors or certain lymphomas whose tumors have a normal p53 gene. The goal is to see if it is safe and helps shrink or slow the cancer.
Canton, OhioAges 18 years+ - NCT07767630RecruitingEarly Phase 1
Targeted radiation therapy for relapsed neuroblastoma
This trial tests a new type of targeted radiation treatment for children and adults with neuroblastoma that has come back or not responded to other treatments. The radiation is attached to a substance that seeks out neuroblastoma cells, aiming to destroy them while limiting harm to healthy tissue.
Chengdu, SichuanAges 1–100 - NCT07066826RecruitingPhase 2/Phase 3
Huperzine A for mild-to-moderate Alzheimer's dementia
This study tests whether Huperzine A controlled-release tablets can help improve memory and thinking in people with mild-to-moderate Alzheimer's disease. You'll take the tablets or a placebo to see if it slows down dementia symptoms.
BeijingAges 50–85 - NCT06925321RecruitingPhase 3
Testing Fosmanogepix for Serious Mold Infections
This trial tests a new drug, Fosmanogepix, for treating serious mold infections that are hard to treat with current medicines. It may be an option for people with limited treatment choices.
Birmingham, AlabamaAges 18 years+ - NCT07600476RecruitingPhase 1
Safety Study of KUP-101A in Advanced Solid Tumors
This is an early-stage study testing a new drug called KUP-101A in patients with advanced solid cancers (like lung, colon, or breast cancer) that haven't responded to standard treatments. The drug works by activating the immune system to fight cancer.
Munich, BavariaAges 18 years+ - NCT07412691RecruitingPhase 1
Safety study of BG-A3004 in healthy people and skin disease patients
This study tests a new drug (BG-A3004) for safety in healthy volunteers and people with certain skin conditions like alopecia areata, cutaneous lichen planus, or vitiligo. It helps find out if the drug is safe and how the body processes it.
Beijing, Beijing MunicipalityAges 18–60 - NCT06511739RecruitingPhase 2
SYHX1901 tablet for non-segmental vitiligo
This study tests an oral tablet called SYHX1901 for people with non-segmental vitiligo. It aims to see if the pill is safe and effective at bringing back skin color.
ShijiazhuangAges 18–65 - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT04829708RecruitingPhase 3
Preventing brain spread in limited-stage small cell lung cancer
This trial compares two ways to manage limited-stage small cell lung cancer that has improved after initial chemotherapy and radiation. Participants will either get preventive brain radiation or have regular brain MRI scans instead, to see which approach is safer and works better.
Jinan, ShandongAges 18–75 - NCT05477849RecruitingPhase 1
Study drug for people with advanced solid tumors
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
Hangzhou, ZhejiangAges 18–75 - NCT04524871RecruitingPhase 1/Phase 2
Immunotherapy combinations for advanced liver cancer
This Phase 1/2 study tests new combinations of immune system medicines in people with advanced liver cancer that cannot be cured by surgery. It looks for safer treatment and signs that the medicines can shrink or control the cancer.
Costa Mesa, CaliforniaAges 18 years+ - NCT03992729Recruiting
Study tracking pregnancy outcomes after tildrakizumab use
This study follows pregnant people who took tildrakizumab to understand pregnancy outcomes and safety. It also compares them with pregnant people with the same underlying disease who did not take tildrakizumab during this pregnancy.
San Diego, CaliforniaAges Any age - NCT05864170RecruitingEarly Phase 1
Tested injection for severe transfusion-dependent thalassemia
This early-stage study tests the safety and possible benefits of an injection called HGI-001 for people with severe transfusion-dependent beta thalassemia. It may help by preparing you for stem cell transplant, but you must meet several health and lab criteria and be able to return often for follow-up tests.
Shenzhen, GuangdongAges 18–35 - NCT05851105RecruitingEarly Phase 1
Study drug for severe alpha thalassemia in people needing regular transfusions
This early-phase trial studies HGI-002 to see if it’s safe and can help people with severe alpha thalassemia who need frequent blood transfusions. It also requires planning for a special treatment approach that includes busulfan pre-treatment and stem cell transplantation.
Nanning, GuangxiAges 12–35 - NCT07074496RecruitingEarly Phase 1
Combined cell therapy for newly diagnosed Ph+ ALL
This trial tests a new combination treatment using ThisCART19A cells and olverembatinib in adults newly diagnosed with a type of leukemia that has the Philadelphia chromosome. It aims to see if this approach is safe and effective.
Suzhou, JiangsuAges 18 years+ - NCT06770569RecruitingPhase 1
Study of HRS-3802 for advanced solid tumors
This trial tests an experimental drug called HRS-3802 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how the body processes it.
Saint Leonards, New South WalesAges 18 years+ - NCT07380334RecruitingPhase 1
Studying SHR-1049 for advanced solid tumors
This study is testing a new drug called SHR-1049 for people with advanced solid tumors (cancers that have spread). It looks at safety, how the drug moves through the body, and whether it helps shrink tumors. You may be eligible if you have tried standard treatment without success or no standard treatment exists.
Hangzhou, ZhejiangAges 18–75 - NCT07695207RecruitingPhase 3
Testing SMZ1 with ranibizumab for wet macular degeneration
This trial tests a new medicine called SMZ1 combined with ranibizumab (a standard treatment) for people with wet macular degeneration. It may help improve vision by targeting the cause of the disease more effectively.
Seoul, SeoulAges 50 years+ - NCT06238401RecruitingPhase 1
Testing ACR246 for advanced solid tumors
This trial tests a new drug called ACR246 for people with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07355972RecruitingEarly Phase 1
CT1195E cell therapy for progressive scleroderma
This trial tests a new cell therapy called CT1195E for people with refractory or progressive systemic sclerosis (scleroderma) that also affects the lungs. It aims to see if the treatment is safe and can help slow or stop the disease.
Wuhan, HubeiAges 18–60 - NCT06975618RecruitingPhase 1/Phase 2
Study of CYH33 for PIK3CA-related overgrowth and vascular malformations
This trial tests a new drug called CYH33 for people with conditions caused by a specific gene mutation (PIK3CA) that leads to abnormal tissue growth or blood vessel problems. It aims to see if the drug is safe and can help shrink or control these growths.
Beijing, Beijing MunicipalityAges Any age
Hear when a new Patient Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for patient safety?
- Yes. Clin2 currently lists 1,355 recruiting patient safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a patient safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a patient safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.